Three potential therapies – including one that could be a lifeline for babies born with a fatal metabolic disorder and another for boys with the muscle-wasting condition Duchenne muscular dystrophy – have become the first to enter a new UK scheme designed to help promising new medicines reach NHS patients faster.

The candidates are recipients of ‘Innovation Passports’ under the new Innovative Licensing and Access Pathway (ILAP), announced today by the ILAP Partners: the Medicines and Healthcare products Regulatory Agency (MHRA), National Health Service (NHS), and the health technology assessment (HTA) bodies – the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC).

The Innovation

See Full Page